<DOC>
	<DOCNO>NCT02942810</DOCNO>
	<brief_summary>This Phase 1 , open label , single-dose , pharmacokinetic study conduct male female subject normal impaired renal function . The study compose five group patient mild ( 6 patient ) , moderate ( 6 patient ) , severe ( 6 patient ) renal impairment , end stage renal disease patient hemodialysis ( 6 patient ) respective match control 1:1 ratio ( 24 healthy subject normal renal function ) . The severity renal impairment assess base estimate creatinine clearance ( CLCR ) Cockcroft-Gault equation</brief_summary>
	<brief_title>To Investigate The Pharmacokinetics Of Intravenous WCK 5222 ( FEP-ZID ) In Patients With Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Cefepime</mesh_term>
	<criteria>1 . Body mass index ( BMI ) 18.0 40.0 ( kg/m2 ) body weight least 50 kg . Patients renal impairment : 2 . Have diagnosis renal impairment stable , without change overall disease status last 1 month Healthy Subjects : 3 . Have normal renal function creatinine clearance 90 mL/min evidence disease condition may affect pharmacokinetics FEP ZID . 4 . A rest blood pressure 90145 ( systolic ) / 6095 ( diastolic ) mmHg healthy volunteer 90155 ( systolic ) / 50100 ( diastolic ) mmHg patient renal impairment . 1 . History presence significant hematologic , pulmonary , cardiovascular , gastrointestinal , neurological , rheumatologic , hepatic , urologic , immunologic , infectious , skin subcutaneous tissue , psychiatric mood disorder ( include past suicide attempt ) , uncontrolled metabolic endocrine disorder ( include diabetes , hypercholesterolemia , dyslipidemia ) opinion Investigator would confound subject 's participation followup clinical trial . 2 . Evidence hepatorenal syndrome acute glomerulonephritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>